Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Schuster

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
The Oncologist|February 3, 2026
Clinical outcomes of Lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancerMargo Brooke Gerke, Akshay Bedmutha, Angelo Marra, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2022
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus <sup>18</sup>F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 TrialIsmaheel O Lawal, Ashesh B Jani, Omotayo A Adediran, et al.
Journal of the American College of Radiology : JACR|May 6, 2017
ACR Appropriateness Criteria<sup>®</sup> Prostate Cancer-Pretreatment Detection, Surveillance, and Staging, Fergus V Coakley, Aytekin Oto, et al.
Journal of the American College of Radiology : JACR|November 6, 2019
ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia, Lauren F Alexander, Aytekin Oto, et al.
Journal of the American College of Radiology : JACR|May 5, 2018
ACR Appropriateness Criteria<sup>®</sup> Post-treatment Follow-up Prostate Cancer, Adam T Froemming, Sadhna Verma, et al.
Clinical Nuclear Medicine|February 8, 2023
Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation TherapyIsmaheel O Lawal, Charles Marcus, David M Schuster, et al.
The Oncologist|July 11, 2026
Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Michelle Jayaraj, et al.
Lancet (London, England)|May 10, 2021
<sup>18</sup>F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trialAshesh B Jani, Eduard Schreibmann, Subir Goyal, et al.
Journal of the American College of Radiology : JACR|May 5, 2018
ACR Appropriateness Criteria<sup>®</sup> Pretreatment Staging of Muscle-Invasive Bladder Cancer, Christian B van der Pol, V Anik Sahni, et al.
European Urology|December 18, 2025
[<sup>18</sup>F]-Fluciclovine or [<sup>68</sup>Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 TrialAshesh B Jani, Vishal R Dhere, Subir Goyal, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
The Oncologist|February 3, 2026
Clinical outcomes of Lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancerMargo Brooke Gerke, Akshay Bedmutha, Angelo Marra, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2022
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus <sup>18</sup>F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 TrialIsmaheel O Lawal, Ashesh B Jani, Omotayo A Adediran, et al.
Journal of the American College of Radiology : JACR|May 6, 2017
ACR Appropriateness Criteria<sup>®</sup> Prostate Cancer-Pretreatment Detection, Surveillance, and Staging, Fergus V Coakley, Aytekin Oto, et al.
Journal of the American College of Radiology : JACR|November 6, 2019
ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia, Lauren F Alexander, Aytekin Oto, et al.
Journal of the American College of Radiology : JACR|May 5, 2018
ACR Appropriateness Criteria<sup>®</sup> Post-treatment Follow-up Prostate Cancer, Adam T Froemming, Sadhna Verma, et al.
Clinical Nuclear Medicine|February 8, 2023
Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation TherapyIsmaheel O Lawal, Charles Marcus, David M Schuster, et al.
The Oncologist|July 11, 2026
Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Michelle Jayaraj, et al.
Lancet (London, England)|May 10, 2021
<sup>18</sup>F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trialAshesh B Jani, Eduard Schreibmann, Subir Goyal, et al.
Journal of the American College of Radiology : JACR|May 5, 2018
ACR Appropriateness Criteria<sup>®</sup> Pretreatment Staging of Muscle-Invasive Bladder Cancer, Christian B van der Pol, V Anik Sahni, et al.
European Urology|December 18, 2025
[<sup>18</sup>F]-Fluciclovine or [<sup>68</sup>Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 TrialAshesh B Jani, Vishal R Dhere, Subir Goyal, et al.
Pageof 18